Q1 26 EPS
$-1.28
MISS 3.68%
Est. $-1.23
Q1 26 Revenue
$1.5M
MISS 65.73%
Est. $4.3M
vs S&P Since Q1 26
+2.9%
BEATING MARKET
CRSP +4.2% vs S&P +1.3%
Market Reaction
Did CRSP Beat Earnings? Q1 2026 Results
CRISPR Therapeutics delivered a disappointing first quarter for fiscal 2026, missing on both the top and bottom lines as revenue of $1.46 million fell 65.73% short of the $4.25 million consensus estimate, despite rising 68.5% year over year, while a … Read more CRISPR Therapeutics delivered a disappointing first quarter for fiscal 2026, missing on both the top and bottom lines as revenue of $1.46 million fell 65.73% short of the $4.25 million consensus estimate, despite rising 68.5% year over year, while a loss of $1.28 per share edged past the $1.23 consensus estimate by 3.68%. The primary culprit behind the revenue shortfall was the modest nature of CRISPR's own recognized revenue, which remains largely limited to collaboration and grant income, even as partner Vertex reported $43.00 million in CASGEVY sales for the quarter, with CRISPR capturing its 40% profit share through a separate collaboration expense structure. Net loss narrowed to $122.93 million from $136.00 million a year ago, aided by reduced R&D and G&A spending. With more than 500 patients globally initiating treatment and Vertex pursuing pediatric label expansion for CASGEVY in children ages 5 to 11, management described the company as entering a second phase, with six pipeline programs across cardiovascular, autoimmune, and oncology indications expected to generate data over the next 12 to 18 months.
Key Takeaways
- • CASGEVY generated $43 million in Q1 2026 revenue with over 500 patients initiating treatment globally
- • Reduced R&D and G&A expenses due to lower employee-related costs
- • Decreased collaboration expense driven by increased share of CASGEVY revenue
- • Strengthened cash position from $585.4 million convertible notes issuance
CRSP Forward Guidance & Outlook
CRISPR Therapeutics expects 2026 to be a defining year. Key milestones include: CTX310 clinical update in H2 2026; CTX460 clinical trial initiation in mid-2026; CTX340 clinical trial initiation in H1 2026; CTX321 Lp(a) program update in 2026; CTX611 Phase 2 update in H2 2026; zugo-cel autoimmune program updates in H2 2026; zugo-cel immuno-oncology updates in H2 2026; Vertex submission for CASGEVY pediatric approval (ages 5-11) under accelerated FDA review; and continued CASGEVY commercial expansion with German pricing agreement implementation. The company has a strengthened balance sheet with $2.4 billion in cash, cash equivalents, and marketable securities following a convertible notes issuance.
CRSP YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
CRSP Revenue by Segment
With YoY comparisons, source: SEC Filings
“The first quarter reflected continued execution across CRISPR Therapeutics' platform. We expanded zugo-cel into new autoimmune indications and advanced multiple in vivo liver-directed programs toward the clinic, while CASGEVY continued its momentum. With a strengthened balance sheet and multiple upcoming milestones, we believe 2026 will be a defining year for CRISPR Therapeutics.”
— Samarth Kulkarni, Q1 2026 Earnings Press Release
CRSP Earnings Trends
CRSP vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
CRSP EPS Trend
Earnings per share: estimate vs actual
CRSP Revenue Trend
Quarterly revenue: estimate vs actual
CRSP Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $-1.23 | $-1.28 | -3.68% | $1.5M | -65.73% |
| Q4 25 MISS FY | $-1.23 | $-1.37 | -11.67% | $864,000 | -78.51% |
| FY Full Year | $-6.17 | $-6.47 | -4.91% | $3.5M | -42.66% |
| Q3 25 BEAT | $-1.29 | $-1.17 | +9.23% | $889,000 | -90.07% |
| Q2 25 MISS | $-1.40 | $-2.40 | -71.55% | $892,000 | -86.15% |
| Q1 25 MISS | $-1.28 | $-1.58 | -23.75% | $865,000 | -85.50% |